Search results
Showing 271 to 285 of 678 results for kidney or kidneys or renal
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Read the biographies of our medical technologies advisory committee members.
Evidence-based recommendations on off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation. This involves inserting artificial chordae that help the mitral valve to close properly.
View recommendations for HTG772Show all sections
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)
Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).
This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.
View quality statements for QS206Show all sections
Sections for QS206
- Quality statements
- Quality statement 1: Preoperative rehabilitation advice for hip and knee replacement
- Statement 2: Choice between partial and total knee replacement
- Statement 3: Tranexamic acid during hip and knee replacement
- Quality statement 4: Preventing implant selection errors
- Statement 5: Postoperative rehabilitation
- Update information
- About this quality standard
Awaiting development Reference number: GID-TA11813 Expected publication date: TBC
administration for NSAIDs in the management of acute pain thought to be due to renal or ureteric stones? Any explanatory notes(if...